The global burden of neurological disease continues to create significant opportunities for pharmaceutical innovation. An estimated 1.2bn people worldwide were living with migraine in 2021, while Parkinson’s disease affected approximately 11.8m people globally. Meanwhile, China’s growing biopharmaceutical sector is reshaping the international licensing landscape, with Chinese biotechnology companies attracting increasing interest from global pharmaceutical developers.

Against this backdrop, Frankfurt-headquartered Merz Therapeutics is pursuing an expansion strategy to double the size of its business by the end of the decade. Rather than diversifying across therapeutic areas, the German drugmaker is concentrating investment in neuroscience, with an increasing focus on neurological pain, including migraine and neuropathic conditions.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The strategy combines internal clinical development with external innovation through acquisitions, licensing agreements and international partnerships. China is emerging as an important part of this approach, not only as a substantial commercial market but also as a source of clinical development opportunities and innovative biotechnology assets.

In conversation with Pharmaceutical Technology at the FT Global Pharma & Biotech Summit in London in November, Merz Therapeutics’ CEO Stefan König explains how the company intends to build scale while maintaining its specialist focus, where it sees opportunities in the evolving neuroscience market, and why pricing, reimbursement and patient access remain significant challenges for the pharmaceutical industry.

This interview has been edited for length and clarity.

Catherine Longworth (CL): You joined Merz Therapeutics in 2023 with a mandate to accelerate the business. What was the ambition when you arrived, and how has the strategy evolved?

Stefan König (SK): It is important to understand Merz Therapeutics in the context of the wider Merz Group. The group comprises three businesses: Merz Therapeutics, Merz Aesthetics and Merz Life Care, which operates primarily in consumer healthcare and over-the-counter pharmaceuticals.

As a family-owned business, the group wanted to ensure that it was not disproportionately exposed to any one of these businesses. The ambition was therefore to bring Merz Therapeutics to a comparable scale to its sister businesses and accelerate its contribution to the group.

Since I joined, we have doubled the size of the organisation and expect to double it again by the end of the decade. That growth will be driven by two principal engines: our own clinical development programmes and external innovation through business development, including acquisitions and licensing.

We have also invested in building an organisation that can support this expansion. That includes a scalable operating model, a matrix structure and additional capabilities in launch and commercial excellence. We are also deploying artificial intelligence (AI) across both commercial operations and research and development.

Importantly, we have advanced several clinical programmes into Phase II and Phase III over the past three years. These programmes are beginning to feature much more prominently in our longer-term business planning.

CL: Merz has established itself as a specialist neuroscience company. Do you see opportunities to broaden the therapeutic focus as the business grows?

SK: Our strategy is to expand through greater depth in neuroscience rather than diversification into other therapeutic areas.

We have a clearly defined footprint covering Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, movement disorders and, increasingly, neurological pain conditions such as migraine and polyneuropathies.

There are adjacent rare and orphan diseases that fit within these areas, but we do not intend to move outside our neuroscience focus. As a mid-sized pharmaceutical company, we need to be disciplined about where we invest and where we believe we can make the greatest difference.

There may be some geographical expansion, although we already have a very global business. Approximately 45% of our revenues come from the US, while a substantial proportion of our European revenues is generated through our own affiliates.

We currently operate in China through distribution partners, so establishing a more direct presence there is a possibility. We may also consider selected opportunities elsewhere in Asia. However, I do not envisage a major geographical transformation of the business. Our priority is to build a stronger portfolio within neuroscience.

CL: How do you differentiate Merz Therapeutics in a competitive neuroscience market increasingly attracting investment from larger pharmaceutical companies?

SK: Large pharmaceutical companies are less present in some of the specialist areas in which we operate, partly because the individual disease markets can be relatively small.

There is also a difference in the types of innovation being pursued. Larger pharmaceutical companies have historically invested heavily in disease-modifying therapies, whereas a significant proportion of our portfolio comprises symptomatic treatments.

Unfortunately, we have seen a number of high-profile failures in late-stage development programmes targeting disease modification. That reinforces the importance of continuing to provide effective symptomatic therapies for patients who need treatment today.

This creates an important role for specialist, mid-sized pharmaceutical companies. We can concentrate on specific neurological conditions and develop treatments that address unmet needs which may not always attract the same level of investment from larger players.

CL: China is becoming an increasingly important player in global pharmaceutical development. What opportunities do you see for Merz Therapeutics in the market?

SK: I see three distinct areas of opportunity. First, China represents a substantial commercial market with a significant patient population and considerable medical need. We have recently signed a co-development agreement for one of our Parkinson’s disease products. Given the scale of the Parkinson’s population in China, bringing innovation to these patients is an important part of our international strategy.

However, China requires a specific development and commercial approach. Companies need either an appropriate local presence or strong strategic partners who understand the market.

Second, China offers opportunities to improve the efficiency of clinical development. Clinical trials can be conducted competitively in terms of both cost and timelines. If we want to accelerate global development programmes and improve their cost efficiency, we need appropriate representation of Chinese patients in international clinical trials.

I am not suggesting that programmes should be conducted exclusively in China. Rather, we need to ensure that Chinese patients are adequately represented in global clinical development.

Third, and increasingly importantly, China is becoming a source of pharmaceutical innovation. Historically, the country has been recognised primarily as a manufacturing centre. That remains important, but I believe its future value to the global pharmaceutical industry will increasingly come from biopharmaceutical innovation.

For Merz, this creates opportunities to acquire, license or establish joint ventures with Chinese biotechnology companies. These three dimensions – the commercial market, clinical development and external innovation – underpin our interest in China.

CL: The international licensing environment has become increasingly competitive. What makes an asset or potential partner attractive to Merz?

SK: Ultimately, we are looking for a drug that makes a meaningful difference for patients and demonstrates that it works. We also need an appropriate risk profile, particularly when we are considering clinical-stage assets or development programmes.

But the quality of the asset is only one part of the equation. The partner is equally important. As a family-owned business, we take a long-term perspective. We consider the value that a treatment can bring to patients and healthcare systems, rather than focusing exclusively on short-term commercial returns.

We look for partners who share that philosophy: organisations with a patient-focused approach, a serious long-term commitment and a strong ethical culture.

Trust is fundamental. If you combine an attractive clinical asset with a partner that shares those values, you have the foundations of a successful collaboration.

CL: Beyond China, the wider pharmaceutical industry continues to face challenges in translating clinical innovation into patient access. Where do you see the greatest obstacles?

SK: For a commercial-stage pharmaceutical company such as Merz, the biggest challenge is pricing, reimbursement and the speed of market access.

We have therapies that were launched in the US several years ago and have entered certain European markets more recently. However, we have still not secured access in other parts of Europe because reimbursement discussions can be prolonged and there are often disagreements between companies and payers about the value of innovation.

The situation varies considerably between European countries, making market access a complex and fragmented process.

Whenever we assess a new clinical innovation, we challenge ourselves with a fundamental question: will healthcare systems pay for this treatment, and will patients be able to access it quickly?

Unfortunately, in Europe, the answer is not always straightforward. The US is different. Innovation is generally more readily recognised and rewarded, including incremental improvements rather than only major advances that fundamentally change treatment paradigms.

In China and Japan, the challenges are somewhat different. There is greater regulatory complexity around ensuring that local patients are appropriately represented in global clinical development programmes.

Ultimately, the ability to demonstrate clinical value is only one part of the equation. We also need regulatory approval, reimbursement and effective market access if we are going to translate innovation into meaningful patient benefit.

CL: What would you identify as the most significant strategic decisions since you took over the business?

SK: The first was the introduction of our Pivot for Growth strategy, which established how we intended to accelerate the development of Merz Therapeutics.

The strategy has provided the framework for doubling the size of the organisation and our ambition to double again over the coming years.

The second was advancing a number of clinical-stage programmes as part of that strategy. These programmes are important because they will provide the basis for future portfolio expansion.

We have also made deliberate choices about our organisational structure. We have adopted a matrix, patient-centric and asset-centric operating model designed to support more effective collaboration across the business.

Finally, we have pursued acquisitions of attractive commercial-stage assets. External innovation is an important complement to our internal development programmes and will remain a central part of our growth strategy.

CL: Looking ahead over the next five years, which clinical programmes and milestones will be most important?

SK: We expect to expand further into neurological pain, building on our established positions in movement disorders, Parkinson’s disease and multiple sclerosis.

Migraine is an important opportunity. We have two global Phase III studies running in parallel, with results expected during the coming year. Subject to positive data and the necessary regulatory approvals, we would expect to move towards commercialising the asset and establishing Merz Therapeutics as a player in migraine prevention.

We believe there is considerable unmet clinical need in migraine. Existing treatments can have significant side effects, and not all patients achieve adequate or sustained control of their condition.

Our approach is based on a different innovation profile from some of the treatments introduced in recent years. We hope to demonstrate improvements in efficacy, safety and ease of use through our clinical development programme.

However, migraine is not the only opportunity in neurological pain. We also have a Phase II programme in neuropathic pain, which has recently reported results and was presented at the Global Pain Congress in Bangkok. We believe the data could provide the basis for progressing into Phase III in the near future, potentially across different neuropathic pain indications and patient populations.

These programmes represent an important next step in broadening our neuroscience portfolio while remaining within our core therapeutic focus.

CL: The migraine market has attracted significant interest from pharmaceutical companies and medical technology developers. How do you see the competitive landscape developing, and where do you believe Merz can differentiate itself?

SK: The first point is that there remains substantial unmet need in migraine.

There are many patients who do not respond adequately to existing therapies, and tolerability and ease of use remain important considerations.

We hope our clinical data will demonstrate a differentiated treatment profile, particularly in terms of efficacy, safety and convenience.

The market is also evolving beyond conventional pharmaceutical treatments, with medical devices and neuromodulation technologies contributing to the range of available approaches.

For us, the priority is to demonstrate meaningful clinical differentiation. We need to show that our approach can offer a genuine improvement for patients, rather than simply adding another treatment option to an already competitive market.

CL: Finally, how important will external innovation and partnerships be to Merz Therapeutics over the next phase of its development?

SK: External innovation will remain fundamental to our strategy.

We are primarily focused on drug development rather than early-stage drug discovery. Consequently, we are continuously looking for the right targets, companies and assets, particularly in the later stages of clinical development within neuroscience.

That applies to opportunities in China, but also to biotechnology companies and pharmaceutical partners in other parts of the world.

We want to identify programmes with attractive clinical potential that can complement our existing portfolio and benefit from our development, regulatory and commercial capabilities.

Our ambition is to build a larger, more competitive neuroscience business, and external partnerships will be an essential part of achieving that.